^
Association details:
| Biomarker: | SETBP1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine
Excerpt:
Patients with SF3B1 mutations showed a better response to AZA (68% vs. 35% responders, P = 0.008). In contrast, subjects with mutations in transcription factors (RUNX1, SETBP1, NPM1) showed a worse response (20% vs. 47% responders, P = 0.014).
DOI:
10.1007/s00277-020-03932-8
